| |
|
Originally developed at Cornell University, “HµRELs”
are patented microfluidic circuits that can reveal interactions among
multiple tissue types and one or more pharmacologic compounds. | | Validation
studies on HµRELs
have yielded metabolic information that was not obtainable from static cell-based
assays or, in certain instances, animal studies or human clinical trials. |
|
HµREL
holds the promise to deliver, early in the preclinical phase, data of dramatically
improved predictive relevancy to the human organism. The Company believes this
capability will enable pharmaceutical researchers to “fail early”
in vitro a significantly higher proportion of the compounds that would
otherwise be promoted into in vivo testing.
Human-relevant.
HµREL®. |
| |
